|Year : 2015 | Volume
| Issue : 2 | Page : 131-137
Association between myasthenia gravis and cognitive function: A systematic review and meta-analysis
Zhifeng Mao, Junjie Yin, Zhengqi Lu, Xueqiang Hu
Department of Neurology, Multiple Sclerosis Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
|Date of Submission||03-Dec-2014|
|Date of Decision||12-Jan-2015|
|Date of Acceptance||01-Mar-2015|
|Date of Web Publication||8-May-2015|
Department of Neurology, Multiple Sclerosis Center, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, Guangdong Province - 510 630
Source of Support: None, Conflict of Interest: None
| Abstract|| |
The course of myasthenia gravis (MG) is complicated by increased reports of cognitive defects in both human and animal models, which suggests potential central nervous system (CNS) damage. We conducted a systematic review of the relationships between MG and cognitive function. This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Major databases were searched to examine the neuropsychological studies of adults with MG. Weighted effect sizes were pooled by cognitive domain. Eight studies representing 300 subjects were included. Eight cognitive domain categories were identified: (i) Mini-Mental State Examination (MMSE), (ii) language, (iii) processing speed, (iv) verbal learning and memory, (v) visual learning and memory, (vi) attention span, (vii) response fluency, and (viii) motor performance. Nine (cognitive domain categories, MMSE, language, processing speed, verbal learning and memory (except for delayed recall memory), and motor performance) of 16 cognitive tasks revealed significant moderate effect sizes. Verbal logical-delayed memory, finger tapping with the preferred hand, and the Symbol Digit Modalities Test showed a greater magnitude relationship to cognitive function than did other specific cognitive domains. Verbal learning and memory seems to be the most significant affected according to cognitive domain categories. For MG, the ability of attention, response fluency, visual learning, and memory seems to be reserved. The MG patients seem to perform significantly worse than the non-MG controls in a range of cognitive domains. Our findings should be interpreted with caution because of the clinical and methodological heterogeneity of included studies.
Keywords: Cognitive impairment, meta-analysis, myasthenia gravis
|How to cite this article:|
Mao Z, Yin J, Lu Z, Hu X. Association between myasthenia gravis and cognitive function: A systematic review and meta-analysis. Ann Indian Acad Neurol 2015;18:131-7
|How to cite this URL:|
Mao Z, Yin J, Lu Z, Hu X. Association between myasthenia gravis and cognitive function: A systematic review and meta-analysis. Ann Indian Acad Neurol [serial online] 2015 [cited 2019 Nov 13];18:131-7. Available from: http://www.annalsofian.org/text.asp?2015/18/2/131/156560
| Introduction|| |
Understanding how disease processes affect functional interactions in the central nervous system (CNS) represents a core challenge of neuroscience research. Currently, myasthenia gravis (MG) is considered to be an uncommon autoimmune neuromuscular disorder. However, the course of MG is complicated by increased reports of cognitive defects in both human and animal models, which may suggest partial or potential CNS damage. ,, The observation of cognitive deficits among many MG patients may have several explanations:
- There may be a hypothetical pathogenic central effect of antibodies (Abs) against the acetylcholine receptor (AChR); 
- certain individuals may not possess protective factors, such as age, disease severity, and type of treatment; 
- mood disturbance; and
- a possible effect of nonspecific immunological processes.
To evaluate these possibilities, researchers have attempted to detect subtle cognitive differences between MG patients and controls; ,, however, the results vary widely across studies because of limited sample sizes and differences in the study populations and evaluation criteria. Thus, there is inadequate conclusive evidence to confirm cognitive deficit in MG patients. To determine whether an association exists between MG and cognitive function decline, we conducted a systematic review and meta-analysis of the literature.
| Materials and Methods|| |
This systematic review was undertaken following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.  We searched Medline, Web of Science, Embase, PsycINFO, and the Chinese Biomedical Research literature to retrieve relevant studies published from inception to July 2014. Various combinations of search terms were used, including; myasthenia gravis, neuropsycholog*, neurocognitive, cognitive, impairment, deficit, and functioning. To identify the articles missed by our original search strategy, we reviewed the references of the identified articles.
Two reviewers (Zhifeng Mao and Xueqiang Hu) screened all abstracts of the identified articles based on the following inclusion criteria:
- The study population consisted of adults (wholly or predominantly);
- a comparison control group (non-MG group) was included;
- the study reported results for one or more separable cognitive domains (i. e., not only the global cognitive status), and
- provided data with reporting of performance means and standard deviation for both patients and controls.
Exclusion criteria included:
- Studies of mixed populations were excluded unless separate results for patients with MG were reported;
- studies investigating individuals with preexisting dementia; and
- reviews, editorials, letters, case series, and case reports.
Two reviewers independently selected studies that fulfilled the inclusion criteria and extracted the MG data and the mean cognitive function scores in the MG and non-MG groups [Table 1]. Missing data were obtained from the authors whenever possible.
Nonrandomized meta-analyses were performed, and study quality was assessed using a modified version of the Newcastle-Ottawa Scale [Table 2]. ,, Up to eight points were assigned to each study based on the quality of the MG and non-MG group selection, comparability of groups, and the cognitive function assessment.
Classification of neuropsychological tests and cognitive domain
Neuropsychological measures were defined by objectively assessing a recognized cognitive domain. Eight cognitive domains categories were identified:
- Mini-Mental State Examination (MMSE),
- Verbal learning and memory,
- Visual learning and memory,
- Attention span,
- Response fluency,
- Motor performance, and
- Processing speed.
The domain of "attention" in the current study refers to immediate memory span ability, as measured by digit span forwards and digit span backwards, and does not reflect more complex attentional processes, such as sustained attention. Neuropsychological instruments that potentially measure separate functions but are traditionally clustered within a single domain (i. e., attentional switching and verbal fluency as both measures of "executive functioning") were analyzed separately because previous research has suggested that the inappropriate aggregation of performances across a range of tests purported to test a common function can obscure the neuropsychological findings. The classification of neuropsychological tests by cognitive domain can be seen in [Table 3].
The pooling of effect sizes and heterogeneity tests was performed using Review Manager 5.2 software. Pooled effect sizes were calculated for each cognitive domain. Random effects modeling for the weighted mean difference was used because it provides a more conservative estimate and, thus, is less likely to overestimate the true effect size. For certain cognitive tests, in which lower scores represented superior performance, the sign of the effect size was reversed to facilitate comparisons across measures. Cohen's classification of effect sizes was used; the effect sizes of d ≤ 0.20 are small, d = 0.50 are medium, and d ≥ 0.80 are large.  Critical values for pooled effect sizes were set at 0.05.
Homogeneity in effect sizes was tested using the Q statistic (χ2 ) for each cognitive domain. To quantify the degree of heterogeneity, the I 2 statistics was also calculated, with the values of 25, 50, and 75% generally reflective of small, moderate, and high heterogeneity, respectively.  A more liberal critical value of 0.10 was used for testing homogeneity because this procedure has been shown to lack power and, as such, was more susceptible to Type II errors (falsely accepting the null hypothesis).
| Results|| |
Our search was performed on December 15, 2013, and it identified 240 articles [Figure 1]. Of these articles, 200 were excluded on the basis of titles or abstracts, and 40 reports were identified for full-text review. One additional report was identified by searching relevant reference lists or by hand searches of the main journals of neurology. Finally, eight studies fulfilled the inclusion criteria and were included in this review. ,,,,,,, The number of patients ranged from 12 to 100. The total number of participants was 300 in the MG group and 179 in non-MG group [Table 1]. All studies used healthy people as controls. All studies had similar age and education for patients and controls.
Seven studies received quality scores of ≥6 (of 8), and the remaining study received a quality score of 5 [Table 2]. Only one study consecutively enrolled patients.  Most studies did not report their enrolment details; thus, it was unclear whether the participants were representative of the population from which they were recruited. None of the studies featured blinded cognitive function assessments. All studies were cross-sectional rather than longitudinal.
Quantitative analysis of cognitive function
We performed meta-analyses of all exposure-outcome associations with two or more separate populations for a total of16 separate meta-analyses. All studies addressing the same domain-specific cognitive function in people with MG were meta-analyzed. The effect size differences for the cognitive variables, together with their confidence intervals, significance tests, and homogeneity statistics, are reported in [Table 3]. Forest plots are displayed in the Appendix 1 [Additional file 1].
Nine (cognitive domain categories, MMSE, language, processing speed, verbal learning and memory (except for delayed recall memory), and motor performance) of 16 cognitive tasks revealed moderate effect sizes. Verbal logical-delayed memory (d = −0.75), finger tapping with the preferred hand (d = −0.75), and the Symbol Digit Modalities Test (d = −0.71) were significantly greater than all other domains; only logical-delayed memory exhibited significant in homogeneity (P = 0.03). Verbal learning and memory domain (logical-immediate memory, logical-delayed memory, and immediate recall memory) seems to be the most significant affected according to cognitive categories. In contrast, there was no evidence of significantly worse MG regarding attention, response fluency, and visual learning and memory [[Table 3] and Appendix 1]. We used sensitivity analyses to assess the robustness of our conclusions. One study used an elderly patient group (mean age, 71.8 years);  after removing this study from our analyses, the results remained nearly the same, except that the significant results found in language testing and delayed recall memory were reversed. Generalized MG (GMG) was the main group in most studies except one study;  after removing this study from our analyses, the results remained nearly the same, except that the ability of language and immediate recall memory found to be reserve in GMG. In addition, language score varies in each study (especially, in Tucker et al. and Paradis et al.). The heterogeneity of scores is explained by the different type of Boston Naming Test (BNT) using shorter and full edition among these studies, with naming nouns 0-30 (30 score at most) in studies of Chen et al., and Marra et al., and naming nouns 0-50 in studies by Tucker et al., and Paradis et al. We then summed upseparate effect size by different naming nouns groups to test the robust of result. However, both patients using BNT 0-30 and 0-50 showed no evidence significantly worse than control groups, with P = 0.11 and 0.15, respectively.
| Discussion|| |
The aims of this systematic review were to describe the literature and to examine the pooled data to evaluate whether adults with MG exhibited worse performance in each of the cognitive domains studies compared to controls without MG. The evidence from this review suggested that:
- The MG patients might perform worse than the non-MG controls in a range of cognitive domains.
- Delayed recall memory seems to also be associated with MG patients after removing the elderly group study using sensitivity analyses. Altogether, the results showed that patients also performed significantly worse in verbal learning and memory tests. However, the ability of immediate recall memory seems to be reserve in GMG patients.
- Verbal logical-delayed memory, finger tapping with the preferred hand, and the Symbol Digit Modalities Test showed a somewhat greater relationship with cognitive function than did other specific cognitive domains; verbal learning and memory domain seems to be the most significant affected according to cognitive categories.
- The ability of attention, response fluency, visual learning, and memory seems to be reserve in MG patients. However, these findings are tentative because of the methodological heterogeneity there is lack of rigorous empirical evidence to support this finding. Several issues need to be borne in mind, however, in the interpretation of these results.
This result could, in theory, be explained by publication bias, the preferential publication of studies that achieve statistical significance and non-publication of studies that do not. However, other explanations may also account for this distribution of data. In particular, this pattern often arises as a result of clinical heterogeneity of the studies. Clearly, studies will employ different inclusion and exclusion criteria, different types of therapists, different types of neuropsychological parameters (i. e., shorter and full edition in the same test, like BNT mentioned in results section), and so on; all of which can have an impact on the effect size. Although there was nearly no statistical evidence of heterogeneity in this meta-analysis (only letter fluency showed high heterogeneity with I 2 = 75%), but power to detect heterogeneity was low because of the small number of available reports. It must also be borne in mind that MG patients included were generally less severely impaired. For example, only outpatients were included in one study.  It is reasonable that increased reports of cognitive defects in MG with more disease severity (in particular, among inpatients and those patients with unstable condition). We recognize that this is likely to be a conservative estimate because underreporting (or under recognition) of cognitive defects in more severe patients.
In addition, one study used patients self-selected inclusion method.  Thus, MG patients with mild cognitive defects may fail to be recruited in the study. This will also cause potential underreporting. Even with above consideration, we still identified some evidence of cognitive deficits in MG patients, although most significantly domains were mild to moderate effect sizes. Finally, the wisdom of the inclusion of unpublished data has been contested. Unpublished studies have not undergone formal peer review; and the fact that the study was not submitted for publication, raises questions about the quality of the work. As a consequence, we still know little about the relationship between cognitive defects and MG.
On the other hand, the lack of statistically significant findings in some neuropsychological parameters, even after pooling, is possibly a result of type 2 error. For example, delayed recall memory was assessed by only two studies in this meta-analysis [Table 3]. The infrequent reporting and small number of patients, make it particularly difficult to demonstrate significant effects.
Our results differ from one published comprehensive narrative review.  The review reported that verbal and visual learning were the cognitive domains most commonly affected in MG. In contrast, our meta-analysis found that only the verbal learning deficit was consistent with previous reviews. The previous conclusions in the original studies were based on whether the relationship between MG and cognitive test scores was statistically significant. Because statistical significance depends on the sample size, solely focusing on this criterion could mask a small consistent effect in underpowered studies. Furthermore, we found that MMSE, logical memory, and motor performance were affected in MG patients; these results were not found in the previous review.
The current study highlighted some of the demographic limitations inherent in the neuropsychological research of MG. In keeping with expectations, the disease subtypes appeared to explain some of the heterogeneity in cognitive outcomes. That is, relative to the controls, the MG patients appeared to show more severe deficits in the cognitive domains. Future studies should consider adjusting the raw scores for severity using normative data from large samples, which would ensure that the patients are compared with more valid controls. This suggestion is particularly important given that normative samples are typically more representative of the general population than small control samples. Furthermore, when additional analyses were conducted and one study with elderly patients was included, as mentioned above, the association between language ability and MG became nonsignificant.  We believe that that this discrepancy indicated that age might partly influence performance on the language ability test.
Strength and limitations
The meta-analysis approach allowed us to calculate pooled results, and thus, offers greater confidence in the results. We used an a priori method to identify 16 cognitive domains and classified the neuropsychological measures by subtests according to these domains to facilitate systematic comparisons. We also examined the potential methodological challenges across the studies to inform future research efforts. The review was limited by the availability of only eight studies that met the inclusion criteria. This finding highlights the paucity of peer-reviewed studies and the methodological complexity of studying this population. The limited availability of independent samples also inhibited the generalizability of the findings. Because of the small number of studies, it was not feasible to conduct meta-regression models with multiple predictors and interactions. Hence, it is difficult to determine whether demographicor clinical characteristics, or a combination of both, were more likely to be associated with neuropsychological heterogeneity. For similar reasons, it is unclear whether different symptom patterns and severity levels, beyond the current characterization of severity as either 'euthymic' or 'symptomatic', were associated with different neuropsychological profiles. Finally, it is quite possible that unpublished studies of nonsignificant differences (the so-called "file drawer problem") are underrepresented. However, due to the small number of identified studies, a funnel plot was not constructed to assess the risk of publication bias.
Recommendations for future research and practice
The greatest differences between the controls and the MG patients were in the areas of verbal logical-delayed memory, finger tapping with the preferred hand, and the Symbol Digit Modalities Test [Table 3]. Therefore, cognitive remediation or training may be an appropriate intervention, although it has not been previously studied in this population. Compensatory cognitive training, for example, has shown positive effects on cognition and functional capacity in multiple sclerosis.  An understanding of the day-to-day impact of any identified deficits would help to determine their clinical significance and identify potential treatment targets. In addition, we found that all analyses yielded effect sizes in the expected direction (poor cognitive function associated with MG samples, see Appendix). However, the fact that most studies found that different cognitive function domains were associated with MG, means that the cognitive function dimensions that are affected by MG are still debatable. We noted one of the included studies that drew conclusion mainly based on the MMSE scale (and memory tests).  However, the MMSE score is a low resolution screening instrument that neither has specificity nor sensitivity (especially for those who have mild cognitive impairment) to draw conclusion. Furthermore, MMSE scores could be easily affected by age, education, and cultural background. We did not exclude this study from our review, but note that it highlights an important methodological issue in studies of future cognitive design.
MG may affect different cognitive domains (depending on differences in how neuropsychological and neurocognitive assessments are conducted) and define cognitive decline. Future studies should examine the relationship between MG and specific (core) cognitive domain function in greater detail. Given the relatively modest effect sizes detected in the current review, it is unlikely that neuropsychological functioning is sensitive enough to diagnose mild cognitive impairment. However, neuropsychological indicators may be more useful in helping clinicians to identify and prioritize their patients' treatment needs at an early phase and monitor treatment responses to programs designed to ameliorate cognitive deficits. Cross-sectional methodology was used nearly in all studies, which limits the conclusions that can be drawn about the impact of the course of MG. Thus, studies examining longitudinal change in cognitive function, particularly after treatment, are needed.
| Conclusion|| |
In conclusion, our study provides some evidence that cognitive functioning is reduced in MG, despite the acknowledged difficulties in analysis of outcome of chronic and rare diseases with unpredictable and fluctuating courses. However, our findings should be interpreted with caution because of the clinical and methodological heterogeneity of included studies. Despite the limitations of meta-analysis and a lack of methodological rigor in the primary studies, we believe our results provide the best picture currently available to inform clinicians, patients, and policy makers about possible cognitive deficits in MG. The review suggests a need to develop and to empirically investigate the feasibility of cognitive rehabilitation at an early stage of the disorder. A number of methodologies should be integrated to explore these hypotheses and further elucidate the underlying mechanisms of MG patients. Additionally, the possible negative impact of medication, number of mood episodes, history of psychotic symptoms, and other clinical cognition variables deserve to be further investigated.
| References|| |
Fulpius BW, Fontana A, Cuenoud S. Central nervous-system involvement in experimental autoimmune myasthenia gravis. Lancet 1977;2:350-1.
Glennerster A, Palace J, Warburton D, Oxbury S, Newsom-Davis J. Memory in myasthenia gravis: Neuropsychological tests of central cholinergic function before and after effective immunologic treatment. Neurology 1996;46:1138-42.
Lanfranconi S, Corti S, Baron P, Conti G, Borellini L, Bresolin N, et al
. Anti-MuSK-positive myasthenia gravis in a patient with parkinsonism and cognitive impairment. Neurol Res Int 2011;2011:859802.
Keesey JC, Tourtellotte WW, Herrmann C Jr, Andrews JM, Lindstrom J. Acetylcholine-receptor antibody in cerebrospinal fluid. Lancet 1978;1:777.
Bartel PR, Lotz BP. Neuropsychological test performance and affect in myasthenia gravis. Acta Neurol Scand 1995;91:266-70.
Lewis SW, Ron MA, Newsom-Davis J. Absence of central functional cholinergic deficits in myasthenia gravis. J Neurol Neurosurg Psychiatry 1989;52:258-61.
Bohbot VD, Jech R, Bures J, Nadel L, Rùzicka E. Spatial and nonspatial memory involvement in myasthenia gravis. J Neurol 1997;244:529-32.
Paul RH, Cohen RA, Gilchrist JM, Aloia MS, Goldstein JM. Cognitive dysfunction in individuals with myasthenia gravis. J Neurol Sci 2000;179:59-64.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009;339:b2535.
Chen WL, Ding L, Guo QH. Cognitive function in patients with myasthenia gravis. Chin J Clin Psychol 2006;14:28-30.
Iwasaki Y, Kinoshita M, Ikeda K, Takamiya K, Shiojima T. Cognitive dysfunction in myasthenia gravis. Int J Neurosci 1990;54:29-33.
Marra C, Marsili F, Quaranta D, Evoli A. Determinants of cognitive impairment in elderly myasthenia gravis patients. Muscle Nerve 2009;40:952-9.
Paradis C, Lazar R, Kula R. Cognitive function in myasthenia gravis. Cogn Behav Neurol 1994;7:211-4.
Sitek EJ, Bilinska MM, Wieczorek D, Nyka WM. Neuropsychological assessment in myasthenia gravis. Neurol Sci 2009;30:9-14.
Tucker DM, Roeltgen DP, Wann PD, Wertheimer RI. Memory dysfunction in myasthenia gravis: Evidence for central cholinergic effects. Neurology 1988;38:1173-7.
Wells GA, Shea B, O'Connell D, Peterson D, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http://wwwohrica/programs/clinical_epidemiology/oxfordasp [Last accessed on 2012 Mar 26] 2000.
Lei C, Lin S, Tao W, Hao Z, Liu M, Wu B. Association between cerebral microbleeds and cognitive function: A systematic review. J Neurol Neurosurg Psychiatry 2013;84:693-7.
Eggermont LH, de Boer K, Muller M, Jaschke AC, Kamp O, Scherder EJ. Cardiac disease and cognitive impairment: A systematic review. Heart 2012;98:1334-40.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
Paul RH, Cohen RA, Zawacki T, Gilchrist JM, Aloia MS. What have we learned about cognition in myasthenia gravis? A review of methods and results. Neurosci Biobehav Rev 2001;25:75-81.
Chiaravalloti ND, Moore NB, Nikelshpur OM, DeLuca J. An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial. Neurology 2013;81:2066-72.
[Table 1], [Table 2], [Table 3]